Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many hepatotoxicity monitoring claims (liver enzymes, baseline, and monthly testing) align with label requirements. However, several management/decision claims (tightening schedule, pausing vs typical discontinuation, retesting after pause, and persistence-based discontinuation) are not supported by the provided label excerpts and therefore reduce alignment.
Category Scores
Accurate Statements
Bosentan can cause liver injury.
TRACLEER 5.1 Hepatotoxicity describes risk of hepatotoxicity with ALT/AST and bilirubin increases.
Liver function tests are required before starting bosentan treatment.
2.1 Required Monitoring: measure liver aminotransferase levels prior to initiation of treatment.
Liver function tests are required at regular intervals during bosentan therapy.
2.1 Required Monitoring: measure prior to initiation and then monthly.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be checked frequently during bosentan treatment.
2.1 Required Monitoring: monthly measurement of liver aminotransferase levels; 5.2 requires prescribers to review serum aminotransferases and agree to order and monitor monthly.
ALT and AST should be checked within baseline assessment prior to the first bosentan dose.
2.1 Required Monitoring: measure liver aminotransferase levels prior to initiation of treatment.
ALT and AST should be checked every month while on bosentan.
2.1 Required Monitoring: then monthly.
Bosentan monitoring focuses on transaminases (ALT and AST).
2.1 and 5.2 specify monitoring serum aminotransferases (ALT/AST) and bilirubin; hepatotoxicity discussion centers on ALT/AST elevations.
Unsupported Statements
If liver enzyme elevations occur, the monitoring schedule is usually tightened.
The provided label excerpts specify monthly measurement and therapy adjusted accordingly, but they do not state that the monitoring schedule is 'usually tightened' after enzyme elevations.
If liver enzyme elevations occur, bosentan dosing may be interrupted depending on severity.
The provided label excerpt (2.4) states discontinue under specific conditions; it does not describe interruption 'depending on severity' or dose interruption language. No reintroduction experience is provided.
If liver enzyme elevations reach clinically significant thresholds, bosentan is typically paused.
The excerpted guidance specifies discontinuation if accompanied by symptoms of hepatotoxicity or bilirubin ≥2 × ULN, but it does not state 'paused' or 'typically' use a threshold-based pause for aminotransferase elevations.
After bosentan is paused for ALT/AST elevations, retesting is done to confirm trends.
The provided label excerpts do not describe retesting after a pause to confirm trends.
If ALT/AST elevations persist or worsen, bosentan treatment may be discontinued.
The provided excerpt states discontinuation based on aminotransferase elevations with accompanying clinical symptoms of hepatotoxicity or bilirubin ≥2 × ULN, and does not provide a 'persist or worsen' rule as stated.
Contradictions
Low
AI Statement
If liver enzyme elevations occur, bosentan dosing may be interrupted depending on severity.
Label Reference
2.4 Dosage Adjustments for Aminotransferase Elevations: Discontinue under specified conditions; no label excerpt supports dosing interruption as a typical management step.
Important Omissions
The label excerpt specifies bilirubin monitoring and discontinuation criteria including bilirubin ≥2 × ULN and discontinuation with clinical symptoms of hepatotoxicity (e.g., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue).
Importance:
Moderate
Bosentan is available only through the Bosentan REMS (prescriber/patient/pharmacy enrollment) due to hepatotoxicity risk.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most monitoring frequency/baseline enzyme requirements are aligned, but management statements about pausing/interruption and retesting after elevations are not supported by the provided label excerpts. This could lead to inaccurate expectations of label-based decision-making for treatment continuation or discontinuation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several liver-elevation management claims (tightening schedule, pausing, retesting after pause, and discontinue based on persistence/worsening) are not supported by the provided label excerpts, which instead describe monthly measurement and discontinuation under specified symptoms/bilirubin criteria.
Suggested Improvement
Revise the management language to match the excerpted label: monthly aminotransferase measurement; discontinue when aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity or when bilirubin ≥2 × ULN; avoid initiating with aminotransferases >3 × ULN; and include bilirubin monitoring and REMS requirement.